Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1112851-50-9

Post Buying Request

1112851-50-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1112851-50-9 Usage

General Description

5,6-Dimethoxypicolinonitrile is a chemical compound with the molecular formula C8H8N2O2. It is a nitrile derivative of picolinonitrile and contains two methoxy groups attached to the 5 and 6 positions of the pyridine ring. 5,6-Dimethoxypicolinonitrile is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also utilized in organic synthesis and chemical research as a building block for the creation of various heterocyclic compounds. Additionally, 5,6-Dimethoxypicolinonitrile has potential applications in the field of medicinal chemistry, where it may be further modified to develop new drug candidates or active pharmaceutical ingredients.

Check Digit Verification of cas no

The CAS Registry Mumber 1112851-50-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,2,8,5 and 1 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1112851-50:
(9*1)+(8*1)+(7*1)+(6*2)+(5*8)+(4*5)+(3*1)+(2*5)+(1*0)=109
109 % 10 = 9
So 1112851-50-9 is a valid CAS Registry Number.
InChI:InChI=1S/C8H8N2O2/c1-11-7-4-3-6(5-9)10-8(7)12-2/h3-4H,1-2H3

1112851-50-9 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (ADE000524)  5,6-Dimethoxypicolinonitrile  AldrichCPR

  • 1112851-50-9

  • ADE000524-1G

  • 7,411.95CNY

  • Detail

1112851-50-9Relevant articles and documents

Discovery of 5″-chloro-n-[(5,6-dimethoxypyridin-2- yl)methyl]-2,2':5',3″-Terpyridine-3'-carboxamide (mk-1064): A selective orexin 2 receptor antagonist (2-sora) for the treatment of insomnia

Roecker, Anthony J.,Mercer, Swati P.,Schreier, John D.,Cox, Christopher D.,Fraley, Mark E.,Steen, Justin T.,Lemaire, Wei,Bruno, Joseph G.,Harrell, C. Meacham,Garson, Susan L.,Gotter, Anthony L.,Fox, Steven V.,Stevens, Joanne,Tannenbaum, Pamela L.,Prueksaritanont, Thomayant,Cabalu, Tamara D.,Cui, Donghui,Stellabott, Joyce,Hartman, George D.,Young, Steven D.,Winrow, Christopher J.,Renger, John J.,Coleman, Paul J.

, p. 311 - 322 (2014/04/03)

The field of small-molecule orexin antagonist research has evolved rapidly in the last 15 years from the discovery of the orexin peptides to clinical proof-of-concept for the treatment of insomnia. Clinical programs have focused on the development of antagonists that reversibly block the action of endogenous peptides at both the orexin 1 and orexin 2 receptors (OX1R and OX2R), termed dual orexin receptor antagonists (DORAs), affording late-stage development candidates including Merck's suvorexant (new drug application filed 2012). Full characterization of the pharmacology associated with antagonism of either OX1R or OX2R alone has been hampered by the dearth of suitable subtype-selective, orally bioavailable ligands. Herein, we report the development of a selective orexin 2 antagonist (2-SORA) series to afford a potent, orally bioavailable 2-SORA ligand. Several challenging medicinal chemistry issues were identified and overcome during the development of these 2,5-disubstituted nicotinamides, including reversible CYP inhibition, physiochemical properties, P-glycoprotein efflux and bioactivation. This article highlights structural modifications the team utilized to drive compound design, as well as in vivo characterization of our 2-SORA clinical candidate, 5''-chloro-N- [(5,6-dimethoxypyridin-2-yl)methyl] -2,2':5',3''-terpyridine-3'-carboxamide (MK-1064), in mouse, rat, dog, and rhesus sleep models.

ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS

-

Page/Page column 48, (2010/05/14)

The present invention is directed to isonicotinamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. Th

PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS

-

Page/Page column 41-42, (2010/12/29)

The present invention is directed to pyrazine carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involve

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1112851-50-9